Truist Securities Maintains Buy on Cormedix, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained its Buy rating on Cormedix and increased the price target from $12 to $17, indicating confidence in the company's future performance.
October 22, 2024 | 5:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has maintained its Buy rating on Cormedix and raised the price target from $12 to $17, suggesting a positive outlook for the company's stock.
The increase in price target from $12 to $17 by Truist Securities, along with the maintained Buy rating, indicates a strong positive sentiment from the analyst. This is likely to lead to a short-term increase in CRMD's stock price as investors react to the upgraded target and continued confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100